Shares in Sanofi (EPA:SASY) (NASDAQ:SNY) and Regeneron (NASDAQ:REGN) fell Friday after the pharmaceutical giants reported mixed results from two phase 3 trials of their investigational chronic ...

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is ...

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers rega ...

Intellia Therapeutics (NTLA) stock drops on safety concern in a Phase 3 trial for gene editing therapy nex-z developed with ...

Futures on Wall Street have declined after a session that left the street disappointed. An appeals court reinstated the ...

About itepekimab Itepekimab is a fully human monoclonal antibody that binds to and inhibits interleukin-33 (IL33), an initiator and amplifier of broad inflammation in COPD. IL33 is thought to be ...

We recently published a list of Did Jim Cramer Nail or Miss These 11 Stock Predictions? In this article, we are going to take ...

These stock indices are all on course for health gains this month, with the DAX leading the way. The German benchmark is on ...

Itepekimab, developed by Sanofi and Regeneron, met its primary endpoint in the AERIFY-1 phase 3 study for COPD, showing a 27% reduction in modera ...

PARIS, France and TARRYTOWN, NY, USA I May 30, 2025 I The AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately controlled chronic ...

Regeneron Pharmaceuticals Inc. closed 50.02% short of its 52-week high of $1,211.20, which the company reached on August 27th ...

Intellia Therapeutics shares fell 25% amid safety concerns in Phase 3 trials. Check out if today's selloff in NTLA stock is a ...